Skip to main content
Premium Trial:

Request an Annual Quote

MiRxes Gets $50M in Series D Funding, Applies to Hong Kong Limited Stock Exchange

NEW YORK – MiRxes said Wednesday that it has completed a Series D funding round totaling $50 million, which will help accelerate the Singapore-based firm's development of cancer early detection blood tests and other preventive healthcare solutions.

According to the company, the funding was anchored by existing and new investors including Beijing Fupu, EDB Investments, and NHH Venture Fund.

"This fresh funding will fuel our ambitious growth plans and enable us to continue making a significant impact in the field of multi-cancer early detection," MiRxes Cofounder and CEO Zhou Lihan said in a statement.

The firm said it will used the investment mainly to scale adoption and penetration of its flagship stomach cancer blood test, GastroClear in major Asia-Pacific markets including Southeast Asia, China, and Japan. The funds will also help it push forward a blood-based colorectal cancer screening test and multi-cancer early detection test.

MiRxes also said that it has filed a listing application with the Stock Exchange of Hong Kong Limited.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.